COVID-19 Misinformation: Parents of Patients May Fall for It
Parents of pediatric patients with cancer were more likely to believe COVID-19 misinformation than parents of children without cancer.
Related Articles
Cilta-cel Demonstrates 99.4% ORR in Lenalidomide-Refractory Myeloma
Patients in the CARTITUDE-4 trial experienced a high response rate to the treatment as early as their first relapse.
Multidisciplinary Infrastructure Streamlines Cancer Care During Drug Shortages
The establishment of a multidisciplinary committee can help identify opportunities to best face the ongoing cancer drug shortage.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to…
Inconsistent Symptom Clusters Warrant Routine Assessments in Older Patients With Cancer
Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.
Meaghan Mooney, B.S.N., RN, OCN, Receives CURE’s 2024 Extraordinary Healer® Award
Over 500 attendees at this in-person event celebrated the incredible efforts made by oncology nurses when caring for patients with cancer.
Opinion: CAR T-Cell Therapy as a Promising Avenue in Glioblastoma Treatment
Oncology nurses can educate their patients on the latest developments in CAR T-cell therapy for the treatment of glioblastoma.
Opening the Conversation Around Palliative Care for Patients With Cancer
An expert discussed a screening tool that she and her colleagues used to connect patients with cancer to palliative care services in a more effective…
FDA Approves First Radioactive Drug for Children With SSTR-Positive GEP-NETs
Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone…
FDA Approves IL-15 Receptor Agonist for BCG-Unresponsive NMIBC
Nogapendekin alfa inbakicept-pmln has been approved for use with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or…